Barclays’s Evolent Health EVH Stock Holding History

Barclays’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$3K	–	7040
2018 Q3	$3K	Buy	+100	New	+$2.38K	﹤0.01%	6881

Other funds holding EVH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's EVH Position: Q1 2026 in Review

Barclays reduced its Evolent Health (EVH) stake by 66% in Q1 2026, selling an estimated $460K and leaving 74,180 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #3787.

Barclays first reported a position in EVH in Q2 2016 and has held it in 40 quarters since. The position peaked at $12.7M in Q2 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

Barclays held 74,180 shares of Evolent Health worth $169K as of Q1 2026.
Barclays sold 144,961 Evolent Health shares in Q1 2026, an estimated $460K.
Evolent Health made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3787 holding.
Barclays first reported a position in Evolent Health in Q2 2016 and has held it in 40 quarters since.
Barclays's Evolent Health position peaked at $12.7M in Q2 2025.
191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.